Skip to content

Noninvasive Physiologic Sensors to Assess Depression

Non-Invasive Physiologic Sensors to Assess Depression

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02568865
Enrollment
50
Registered
2015-10-06
Start date
2016-01-15
Completion date
2020-01-03
Last updated
2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Major Depressive Disorder

Brief summary

This project aims to use sensors to monitor physiological signals, sleep patterns, vocal characteristics, activity, location and phone usage in study patients with depression who are receiving standard treatment (compared with healthy controls).

Interventions

OTHERPhysiological Sensors

Wearable biosensors can play an important role in depression diagnosis. For this study, we will use a cost-effective, unobtrusive, and non-stigmatizing sensor to monitor physiological signals (including heart rate (HR), heart rate variability (HRV), electrodermal activity (EDA), physical activity, and temperature).

OTHERSleep Monitoring Device

The X4 Device is an internally battery powered FDA-classified Type BF device used for configurable acquisition of physiological signals via EEG.

OTHERVocal Monitoring

The participants will be provided with a phone app to leave audio diary recordings.

A mobile phone and tablet will be used for various purposes, including, recording of socialization, location, and activity patterns of participants and to collect emotional information based on interactive surveys, as well as for forwarding sleep and physiological sensor measurements to a secure server.

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

Patients with Depression (n=40): 1. Adults (ages 18-75), 2. Able to read, understand, and provide written informed consent in English, 3. Meet criteria for a primary psychiatric diagnosis of major depressive disorder for ≥ 4 weeks, according to the M.I.N.I (Mini International Neuropsychiatric Interview), 4. Hamilton Depression Rating Scale (HDRS) total score ≥ 18, 5. Engaged in or willing to be referred for clinical care for depression treatment as usual (antidepressants and/or psychotherapy), 6. Must have measurable skin conductance/electrodermal activity (as assessed at the screening visit), 7. Must own a working Android smartphone (Android 2.3+) and use it regularly, 8. Must own a windows PC (or tablet) or a Mac computer (or laptop), 9. Must have access to Internet service every day. Healthy Controls (n=10): 1. Adults (ages 18-75), 2. Able to read, understand, and provide written informed consent in English, 3. Not meet criteria for past or current psychiatric illness, excluding specific phobias, as measured by the M.I.N.I., 4. Not have a first-degree relative with known major psychiatric illness including Major Depressive Disorder, Bipolar Disorder, Psychotic Disorder or Substance Use Disorder, 5. Must have measurable skin conductance/electrodermal activity (as assessed at the screening visit), 6. Must own a working Android smartphone (Android 2.3+) and use it regularly, 7. Must own a windows PC (or tablet) or a Mac computer (or laptop), 8. Must have access to Internet service every day.

Exclusion criteria

(for all subjects): 1. Active drug or alcohol use disorder in the past 3 months, 2. History of psychosis, 3. History of mania or hypomania, 4. Epilepsy or history of seizures, 5. Untreated hypothyroidism, 6. Unstable medical disease, 7. Cognitive impairment that would impede adherence to study procedures, 8. Acute suicide or homicide risk, 9. Current treatment with electroconvulsive therapy, vagal nerve stimulation therapy, deep brain stimulation, transcranial magnetic stimulation therapy, or phototherapy, 10. Concurrent participation in other research studies, 11. Cannot comprehend or communicate in English, 12. Lack of working smartphone or lack of daily access to Internet service, 13. Inability to measure skin conductance/electrodermal activity (as assessed at the screening visit), and 14. Inability or unwilling to, at minimum, wear the physiological sensor (E4) bands, fill out the surveys, and record a weekly diary.

Design outcomes

Primary

MeasureTime frameDescription
Physiologic Biorhythms (heart rate)8 weeksWe will measure the heart rate at baseline and during the treatment period. We will compare the corresponding patterns in patients with depression, as well as in healthy controls.
Phone Usage8 weeksWe will measure the cell-phone usage (in the form of texts, web browsing, and phone calls) at the beginning of the study and during the treatment period. We will compare the corresponding phone usage patterns in patients with depression, as well as in healthy controls.
Voice Characteristics8 weeksWe will measure the voice characteristics (via reading a 30-second script as part of an audio diary) at the beginning of the study and during the treatment period. We will compare the corresponding voice characteristics in patients with depression, as well as in healthy controls.
Physiologic Biorhythms (Skin conductance)8 weeksWe will measure the skin conductance at baseline and during the treatment period. We will compare the corresponding patterns in patients with depression, as well as in healthy controls.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026